Compare FGBI & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | LENZ |
|---|---|---|
| Founded | 1934 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.1M | 155.5M |
| IPO Year | 2014 | 2021 |
| Metric | FGBI | LENZ |
|---|---|---|
| Price | $8.68 | $5.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $44.00 |
| AVG Volume (30 Days) | 14.5K | ★ 708.4K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | N/A | ★ $19,088,000.00 |
| Revenue This Year | $567.70 | $50.42 |
| Revenue Next Year | N/A | $197.16 |
| P/E Ratio | $26.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.31 | $4.54 |
| 52 Week High | $11.02 | $50.19 |
| Indicator | FGBI | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 34.79 | 43.75 |
| Support Level | $7.83 | $4.71 |
| Resistance Level | $9.24 | $6.18 |
| Average True Range (ATR) | 0.33 | 0.36 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 13.08 | 13.15 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana through several banking facilities. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and, to a lesser extent, consumer and multifamily loans. The company is engaged in a single line of business as a financial institution, which provides a full range of banking, financial, and trust services to state, county, and local government entities, individuals, and small and commercial businesses.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.